Skip to main content Accessibility help
×
Home
  • Print publication year: 2008
  • Online publication date: August 2009

4 - HIV and Viral Hepatitis

Summary

BACKGROUND

Communities and populations at high risk for HIV infection are also likely to be at risk for coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV). HIV, HBV, and HCV are bloodborne pathogens transmitted through similar routes, for example, via injection drug use (IDU), sexual contact, or from mother to child during pregnancy or birth. A substantial proportion of HIV-infected individuals are coinfected with HBV, HCV, or both viruses, and in the context of effective HIV therapy, liver-related morbidity and mortality among HIV patients is a significant challenge. Current approaches to management of HIV/HBV and HIV/HCV coinfection are detailed in this course.

HEPATITIS C IN THE HIV-INFECTED PATIENT

Epidemiology

HCV and HIV have similar modes of transmission, but the transmission efficiency of each virus differs substantially. HCV is primarily transmitted by percutaneous exposure to blood – namely, via IDU. Coinfection with HCV and HIV is relatively common given the shared routes of transmission, and about 30% of all HIV-infected persons in the United States are also infected with HCV. The prevalence of HIV/HCV coinfection varies depending on the route of HIV transmission, ranging from 10–14% among persons reporting high-risk sexual exposure to approximately 85–90% among those reporting IDU. Despite the lower prevalence of chronic HCV infection among persons not engaged in IDU, recent outbreaks of acute HCV infection have been reported among HIV-infected men who have sex with other men, particularly those who engage in unprotected, traumatic sexual practices.

Related content

Powered by UNSILO
REFERENCES
Koziel, MJ, Peters, MG. Viral hepatitis in HIV infection. N Engl J Med 2007; 356(14):1445–54.
Sherman, KE, Rouster, SD, Chung, R, Rajicic, N. Hepatitis C prevalence in HIV-infected patients: a cross-secctional analysis of the US adult clinical trials group. Antiviral Therapy 2000 (suppl 1) 2000;5:64.
Sulkowski, MS, Thomas, DL. Hepatitis C in the HIV-Infected Person. Ann Intern Med 2003;138(3):197–207.
Danta, M, Brown, D, Bhagani, S, Pybus, OG, Sabin, CA, Nelson, M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007;21(8):983–91.
Thomas, DL, Astemborski, J, Rai, RM, Anania, FA, Schaeffer, M, Galai, N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284(4):450–6.
Eyster, ME, Diamondstone, LS, Lien, JM, Ehmann, WC, Quan, S, Goedert, JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993;6:602–10.
Goedert, JJ, Eyster, ME, Lederman, MM, Mandalaki, T, Moerloose, P, White, GC, et al. End-stage liver disease in persons with hemophilia and transfusion- associated infections. Blood 2002;100(5):1584–9.
Graham, CS, Baden, LR, Yu, E, Mrus, JM, Carnie, J, Heeren, T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis c virus infection: a meta-analysis. Clin Infect Dis 2001;33(4):562–9.
Gebo, KA, Diener-West, M, Moore, RD. Hospitalization rates differ by hepatitis C satus in an urban HIV cohort. J Acquir Immune Defic Syndr 2003;34(2):165–73.
Weber, R, Sabin, CA, Friis-Moller, N, Reiss, P, El Sadr, WM, Kirk, O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166(15):1632–41.
Strader, DB, Wright, T, Thomas, DL, Seeff, LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39(4):1147–71.
Alberti, A, Clumeck, N, Collins, S, Gerlich, W, Lundgren, JD, Palu, G, et al. Short statement of the first european consensus conference on the treatment of chronic hepatitis B and C in HIV-coinfected patients. J Hepatol 2005;42(5):615–24.
Benson, CA, Kaplan, JE, Masur, H, Pau, A, Holmes, KK. Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents. MMWR 2004;53(RR15):1–112.
Soriano, V, Puoti, M, Sulkowski, M, Cargnel, A, Benhamou, Y, Peters, M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007;21(9):1073–89.
Torriani, FJ, Rodriguez-Torres, M, Rockstroh, JK, Lissen, E, Gonzalez-Garcia, J, Lazzarin, A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351(5):438–50.
Chung, RT, Andersen, J, Volberding, P, Robbins, GK, Liu, T, Sherman, KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351(5):451–9.
Carrat, F, Bani-Sadr, F, Pol, S, Rosenthal, E, Lunel-Fabiani, F, Benzekri, A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292(23):2839–48.
Laguno, M, Murillas, J, Blanco, JL, Martinez, E, Miquel, R, Sanchez-Tapias, JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18(13):F27–36.
Payan, C, Pivert, A, Morand, P, Fafi-Kremer, S, Carrat, F, Pol, S, et al. Rapid and early virological response to chronic Hepatitis C treatment with IFN alpha-2b or PEG- IFN alpha-2b plus ribavirin in HIV/HCV co-infected patients. Gut 2007.
Fleischer, R, Boxwell, D, Sherman, KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 2004;38(8):e79–e80.
Alvarez, D, Dieterich, DT, Brau, N, Moorehead, L, Ball, L, Sulkowski, MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006;13(10):683–9.
Sulkowski, MS, Dieterich, DT, Bini, EJ, Brau, N, Alvarez, D, DeJesus, E, et al. Epoetin Alfa Once Weekly Improves Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated With Interferon/Ribavirin: A Randomized Controlled Trial. J Acquir Immune Defic Syndr 2005;39(4):504–6.
Mehta, SH, Lucas, GM, Mirel, LB, Torbenson, M, Higgins, Y, Moore, RD, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006;20(18):2361–9.
Thomas, DL, Cannon, RO, Shapiro, CN, Hook, EW, Alter, MJ, Quinn, TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 1994;169(5):990–5.
Gilson, RJC, Hawkins, AE, Beecham, MR, Ross, E, Waite, J, Briggs, M, et al. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection. AIDS 1997;11(5):597–606.
Kellerman, SE, Hanson, DL, McNaghten, AD, Fleming, PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188(4):571–7.
Shire, NJ, Rouster, SD, Rajicic, N, Sherman, KE. Occult Hepatitis B in HIV-Infected Patients. J Acquir Immune Defic Syndr 2004;36(3):869–75.
Iloeje, UH, Yang, HI, Su, J, Jen, CL, You, SL, Chen, CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130(3): 678–86.
Chen, CJ, Yang, HI, Su, J, Jen, CL, You, SL, Lu, SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295(1):65–73.
Thio, CL, Netski, DM, Myung, J, Seaberg, EC, Thomas, DL. Changes in hepatitis B virus DNA levels with acute HIV infection. Clin Infect Dis 2004;38(7):1024–9.
Soriano, V, Puoti, M, Bonacini, M, Brook, G, Cargnel, A, Rockstroh, J, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005;19(3):221–40.
Thio, CL, Seaberg, EC, Skolasky, RL, Phair, J, Visscher, B, Munoz, A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002;360:1921–6.
Sulkowski, MS, Thomas, DL, Mehta, SH, Chaisson, RE, Moore, RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35(1):182–9.
Gandhi, RT, Wurcel, A, Lee, H, McGovern, B, Boczanowski, M, Gerwin, R, et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis 2003;36(12):1602–5.
Gandhi, RT, Wurcel, A, Lee, H, McGovern, B, Shopis, J, Geary, M, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005;191(9):1435–41.
Di, M, Thevenot, V,Colin, T,Boyer, JF,Martinot, N,Degos, M,, F, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002;123(6):1812–22.
Dore, GJ, Cooper, DA, Barrett, C, Goh, , Thakrar, B, Atkins, M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999;180(3):607–13.
Benhamou, Y, Bochet, M, Thibault, V, DiM, V M, V, Caumes, E, Bricaire, F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30(5):1302–6.
Tenney, DJ, Levine, SM, Rose, RE, Walsh, AW, Weinheimer, SP, Discotto, L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004;48(9):3498–507.
Pessoa, W, Gazzard, B, Huang, A, Brandao-Mello, C, Cassetti, L, Correa, M, et al. Entecavir in HIV/HBV co-infected patients:safety and efficacy in a phase II study (ETV-038). 12th Conference on Retroviruses and Opportunistic Infections 2005;Abstract 123.
McMahon, MA, Jilek, BL, Brennan, TP, Shen, L, Zhou, Y, Wind-Rotolo, M, et al. The HBV drug entecavir – effects on HIV-1 replication and resistance. N Engl J Med 2007;356(25):2614–21.
Benhamou, Y, Thibault, V, Calvez, V, Vig, P, Valantin, MA, Guyon, P, et al. Three-year treatment with adefovir dipivoxil in chronic hepatitis B patients with lamivudine-resistant HBV and HIV co-infection results in significant and sustained clinical improvement. 11th Conference on Retroviruses and Opportunistic Infections Abstract 835. 2004.
Thio, CL. Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer?J Hepatol 2005.
Bommel, F, Wunsche, T, Mauss, S, Reinke, P, Bergk, A, Schurmann, D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40(6):1421–5.
Peters, MG, Anderson, J, Lynch, P, Jacobson, J, Sherman, K, Alston-Smith, B, et al. Tenofovir Disoproxil Fumarate is not inferior to adefovir dipivoxil for the treatment of hepatitis B virus in subjects who are co-infected with HIV: results of ACTG A5127. 12th Conference on Retroviruses and Opportunistic Infections 2005;Abstract 124.
Lim, SG, Ng, TM, Kung, N, Krastev, Z, Volfova, M, Husa, P, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006;166(1):49–56.
Dore, GJ, Cooper, DA, Pozniak, AL, DeJesus, E, Zhong, L, Miller, MD, et al. Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy-Naive and -Experienced Patients Coinfected with HIV-1 and Hepatitis B Virus. J Infect Dis 2004;189(7): 1185–92.
Nelson, M, Portsmouth, S, Stebbing, J, Atkins, M, Barr, A, Matthews, G, et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co- infected individuals. AIDS 2003;17(1):F7–F10.
Fonseca, MO, Pang, LW, Paula, CN, Barone, AA, Heloisa, LM. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005;23(22):2902–8.